[Simultaneous detection of hepatitis B virus surface antigen (HBsAg) and hepatitis C virus (HCV) related antibodies by an immunochromatographic test method using synthesized oligonucleotide-bound protein probes, OligoFast].

An immunochromatographic test using synthesized oligonucleotide-bound protein probes, OligoFast (Nissui Pharmaceutical Co., Ltd., Tokyo) was developed and evaluated for simultaneous detection of hepatitis B surface antigen (HBsAg) and antibodies related with hepatitis C virus (HCV). The color development of colloidal gold was visually read and easily interpretable for the respective antigen and antibody, positive or negative. When the performance panels of Boston Biomedica Inc. (BBI) for HBsAg and HCV-related antibodies were assayed, the results indicated; first, the most positive specimens with 1.2 IU/ml of HBsAg were correctly determined as positive, and secondly, all the positive specimens for HCV-related antibodies confirmed with Ortho RIBA 3.0 were consistently determined as positive and additional two undetermined specimens were interpreted as positive. However, when the seroconversion panel of BBI for hepatitis B virus (HBV) infection, the seroconversion was delayed 20 to 30 days when compared to HBV DNA detection. When the clinical serum specimens were tested in comparison with the automated AxSYM (Abbott Laboratories, Abbott Park, IL, U.S.A.), both sensitivity and specificity were estimated to be 100% for HBsAg, and 91.3% and 99.0% for HCV-related antibodies, respectively. With these results, we can conclude that this newly developed immunochromatographic test will be applicable to simultaneous detection of HBsAg and HCV-related antibodies in a single device, and will be expected to be widely applied in a clinical setting.